MedPage Today 
(5/22, Bankhead) reports, "Mortality risk decreased by more than 40%
in patients whose early-stage kidney cancer was treated by partial
versus radical nephrectomy," according to research presented at a
urology meeting. The analysis of a National Cancer Institute (NCI)
database revealed that "patients younger than 75 had a 53% reduction in
the mortality hazard when they underwent nephron-sparing surgery instead
of radical nephrectomy, and a higher comorbidity score was associated
with an even greater mortality benefit."
The study's lead author pointed out, "The magnitude of the benefit
increased with follow-up."
(5/22, Bankhead) reports, "Mortality risk decreased by more than 40%
in patients whose early-stage kidney cancer was treated by partial
versus radical nephrectomy," according to research presented at a
urology meeting. The analysis of a National Cancer Institute (NCI)
database revealed that "patients younger than 75 had a 53% reduction in
the mortality hazard when they underwent nephron-sparing surgery instead
of radical nephrectomy, and a higher comorbidity score was associated
with an even greater mortality benefit."
The study's lead author pointed out, "The magnitude of the benefit
increased with follow-up."
Axitinib May Help As First-Line Treatment For Metastatic Renal Cell Carcinoma.
MedPage Today
(5/22, Gever) reports, "The angiogenesis blocking drug axitinib
(Inlyta), currently approved as a second-line treatment in advanced
kidney cancer, might also be useful in treatment-naive patients,"
according to a phase II study of "previously untreated patients with
metastatic renal cell carcinoma." Notably, "much of the benefit was
concentrated in patients with high blood levels of the drug, which has
notoriously unpredictable pharmacokinetics. Patients showing substantial
increases in diastolic blood pressure also were
more likely to achieve objective responses."
(5/22, Gever) reports, "The angiogenesis blocking drug axitinib
(Inlyta), currently approved as a second-line treatment in advanced
kidney cancer, might also be useful in treatment-naive patients,"
according to a phase II study of "previously untreated patients with
metastatic renal cell carcinoma." Notably, "much of the benefit was
concentrated in patients with high blood levels of the drug, which has
notoriously unpredictable pharmacokinetics. Patients showing substantial
increases in diastolic blood pressure also were
more likely to achieve objective responses."
No comments:
Post a Comment